Skip to main content

Table 4 GEE analysis of the interaction of group and time on EMG_NCV indices

From: Lithium and preventing chemotherapy-induced peripheral neuropathy in breast cancer patients: a placebo-controlled randomized clinical trial

Variable

 

B

Std. error

Wald chi-square

P value

Ulnar NCV

G2/1 * T9/0

3.222

3.5649

.817

.366

G2/1 * T3/0

5.000

3.3491

2.229

.135

G2/1 * T9/3

− 1.778

1.4577

1.487

.223

Ulnar Amp

G2/1 * T9/0

.333

.3128

1.136

.287

G2/1 * T3/0

− .117

.4228

.076

.783

G2/1 * T9/3

.450

.3670

1.503

.220

Median NCV

G2/1 * T9/0

.500

2.6094

.037

.848

G2/1 * T3/0

2.889

3.2224

.804

.370

G2/1 * T9/3

− 2.389

1.9513

1.499

.221

Median Amp

G2/1 * T9/0

− .222

.2185

1.034

.309

G2/1 * T3/0

.100

.3142

.101

.750

G2/1 * T9/3

− .322

.3191

1.019

.313

Tibial NCV

G2/1 * T9/0

.056

2.6936

.000

.984

G2/1 * T3/0

1.889

3.3171

.324

.569

G2/1 * T9/3

− 1.833

2.3878

.589

.443

Tibial Amp

G2/1 * T9/0

− .244

.1706

2.052

.152

G2/1 * T3/0

− .150

.2017

.553

.457

G2/1 * T9/3

− .094

.1605

.346

.556

Proneal NCV

G2/1 * T9/0

.083

2.7807

.001

.976

G2/1 * T3/0

3.056

3.7217

.674

.412

G2/1 * T9/3

− 2.972

2.1796

1.860

.173

Proneal Amp

G2/1 * T9/0

− .067

.2034

.107

.743

G2/1 * T3/0

.022

.2310

.009

.923

G2/1 * T9/3

− .089

.1557

.326

.568

Symptoms

Group 2/1

.138

.19

.54

.386

time

.061

.01

55.99

<.001

G2*T9/0

− .003

.01

.05

.352

  1. G2/1: Group 2 compared to group 1
  2. T9/0: 9th months compared to start time
  3. T3/0: 3rd months compared to start time
  4. T9/3: 9th months compared to 3rd months
  5. NCV nerve conduction velocity, Amp amplitude